An in vitro dormancy model of estrogen-sensitive breast cancer in the bone marrow: A tool for molecular mechanism studies and hypothesis generation

Journal of Visualized Experiments

Volumn 2015, Issue 100, 2015, Pages

  Tivari, Samir ^a   Korah, Reju ^a   Lindy, Michael ^a   Wieder, Robert ^a  

^a New Jersey Medical School University Hospital Cancer Center   (United States)

Author keywords

Bone marrow stroma; Breast cancer; Colony assay; Dormancy; FGF 2; Fibronectin; Issue 100; Medicine

Indexed keywords

ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHO KINASE;

ANTAGONISTS AND INHIBITORS; BONE MARROW CANCER; BREAST TUMOR; FEMALE; HUMAN; MCF 7 CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY;

BONE MARROW NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MCF-7 CELLS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RHO-ASSOCIATED KINASES;

EID: 84941253843     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/52672     Document Type: Article

References (37)

1. Braun, S., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 342 (8), 525-533, doi:10.1056/NEJM200002243420801, (2000).
2. Benoy, I.H., et al. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res. 7 (2), R210-9, doi:10.1186/bcr980, (2005).
3. Wapnir, I.L., Barnard, N., Wartenberg, D., & Greco, R.S. The inverse relationship between microvessel counts and tumor volume in breast cancer. Breast J. 7 (3),184-188, doi:10.1046/j.1524-4741.2001.007003184.x, (2001).
4. Wyckoff, J.B., et al. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. 60 (9), 2504-2511, PMid:10811132, (2000).
5. Phadke, P.A., et al. Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res. 12 (5), 1431-1440, doi:0.1158/1078-0432.CCR-05-1806, (2006).
6. Braun, S., et al. Lack of an effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J Clin Onc. 18 (1), 80-86, PMid:10623696, (2000).
7. Korah, R., Boots, M., & Wieder, R. Integrin α5β1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 64 (13), 4514-4522, doi:10.1158/0008-5472.CAN-03-3853, (2004).
8. Najmi, S., Korah, R., Chandra, R., Abdellatif, M., & Wieder, R. Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin Cancer Res. 11 (5), 2038-2046, doi:10.1158/1078-0432.CCR-04-1083, (2005).
9. Braun, S., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N England J Med. 353 (8), 793-802, doi:10.1056/ NEJMoa050434, (2005).
10. Dent, R., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13 (15 Part 1), 4429-4434, doi:10.1158/1078-0432.CCR-06-3045, (2007).
11. Kim, R.S., et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One. 7 (4), e35569, doi:10.1371/journal.pone.0035569, (2012).
12. Hanin, L. Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment. Adv in Exp Med & Biol. 734, 261-282 doi:10.1007/978-1-4614-1445-2 (2013).
13. Wilkie, K.P. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy. Adv in Exp Med & Biol. 734, 201-234 doi:10.1007/978-1-4614-1445-2 (2013).
14. Barkan, D., & Green, J.E. An in vitro system to study tumor dormancy and the switch to metastatic growth. J Vis Exp. 54, e2914, doi: 10.3791/2914, (2011).
15. Barrios, J., & Wieder, R. Dual FGF-2 and intergrin α5β1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. Cancer Microenvironment. 2 (1), 33–47, doi: 10.1007/s12307-009-0019-6 (2009).
16. Ganapathy, V., et al. Luminal breast cancer metastasis is dependent on estrogen signaling. Clin & Exp Metastasis. 29 (5), 493-509, doi:10/1007/s10585-012-9466-4, (2012).
17. Barkan, D., et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68 (15), 6241-6250, 10.1158/0008-5472.CAN-07-6849, (2008).
18. Ghajar, C.M., et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biology. 15 (7), 807-817, doi: 10.1038/ncb2767, (2013).
19. Marshall, J.C., et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Nat Cancer Inst. 104 (17),1306-1319, doi: 10.1093/jnci/djs319, (2012).
20. Almog, N. Genes and regulatory pathways involved in persistence of dormant micro-tumors. Adv in Exp Med & Biol. 734, 3-17 doi:10.1007/978-1-4614-1445-2, (2013).
21. Wang, H., et al. Basic FGF causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res. 57 (9), 1750-1757, PMid:9135019. (1997).
22. Fenig, E., et al. Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. Breast Cancer Res Treat. 70 (1), 27-37, doi: 10.1023/A:1012522321762, (2001).
23. Fenig, E., et al. Basic fibroblast growth factor confers growth inhibition and Mitogen-activated Protein Kinase activation in human breast cancer cells. Clinical Cancer Research. 3 (1): 135-142, PMid:9815549. (1997).
24. Coleman-Krnacik, S., & Rosen, J.M. Differential temporal and spatial gene expression of fibroblast growth factor family members during mouse mammary gland development. Molecular Endocrinology. 8 (2), 218-229, doi: 10.1210/mend.8.2.8170478, (1994).
25. Plath, A., et al. Expression and localization of members of the fibroblast growth factor family in the bovine mammary gland. J Dairy Science. 81 (10), 2604-2613, doi:10.3168/jds.S0022-0302(98)75818-7, (1998).
26. Lavandero, S., Chappuzeau, A., Sapag-Hagar, M., & Oka, T. In vivo and in vitro evidence of basic fibroblast growth factor action in mouse mammary gland development. FEBS letters. 439 (3), 351-356, doi:10.1016/S0014-5793(98)01370-2, (1998).
27. Sinowatz, F., Schams, D., Plath, A., & Kolle, S. Expression and localization of growth factors during mammary gland development. Adv in Exp Med & Biol. 480, 19-25, doi: 10.1007/0-306-46832-8_3, (2000).
28. Korah, R., Sysounthone, V., Scheff, E., & Wieder, R. Intracellular FGF-2 promotes differentiation in T47-D breast cancer cells. Biochem Biophys Res Comm. 277 (1), 255-260, doi:10.1006/bbrc.2000.3655, (2000).
29. Korah, R., Das, K., Lindy, M.E., Hameed, M., & Wieder, R. Co-ordinate loss of FGF-2 and laminin 5 expression during neoplastic progression of mammary duct epithelium. Human Pathology. 38 (1), 154-160, doi:10.1016/j.humpath.2006.07.004, (2007).
30. Wieder, R. et al. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation. J. Cellular Physiology. 177 (3), 411-425, doi: 10.1002/(SICI)1097-4652(199812)177:3<411::AIDJCP5> 3.0.CO;2-Y, (1998).
31. Brunner, G., Gabrilove, J., Rifkin, D.B., & Wilson, E.L. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol. 114 (6), 1275-1283, doi:10.1083/jcb.114.6.1275, (1991).
32. Wilson, E.L., Rifkin, D.B., Kelly, F., Hannocks, M.J., & Gabrilove, J.L. Basic fibroblast growth factor stimulates myelopoiesis in long-term human bone marrow cultures. Blood. 77 (5), 954-960, PMid:1995102, (1991).
33. Gupta, P., McCarthy, J.B., & Verfaillie, C.M. Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells. Blood. 87 (8), 3229-3236, PMid:8605338, (1996).
34. Chatterjee, M., & van Golen, K.L. Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype. Int J Cancer. 129 (1), 61-69, doi: 10.1002/ijc.25655, (2011).
35. Korah, R., Sysounthone, V., Golowa, Y. and Wieder, R. Basic fibroblast growth factor confers a more differentiated phenotype in MDAMB- 231 human breast cancer cells. Cancer Res. 60 (3), 733-740, PMid:10676661, (2000).
36. Dontu, G., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes & Dev. 17 (10), 1253-1270, doi: 10.1101/gad.1061803, (2003).
37. Tivari, S., Lu, H., Dasgupta, T., & Wieder, R. Reactivation of dormant estrogen-dependent breast cancer micrometastases by bone marrow stromal injury in an in vitro model of dormancy. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research. Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; (2014).